is...(ListenLearnLead)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Congratulations @MushroomsInc in advance on your progress with patents. Looking forward to updates.
— Branded Legacy, Inc. $BLEG (@BrandedLegacy) September 14, 2023
😁$MSRM 🍄#mushrooms #mushroom #Growth $BLEG https://t.co/JGOsIiSMSJ
$MSRM #biotech connections/partnership ??? #lowfloat ##OTC https://t.co/vJplX5L7Pu
— JPA (@j77tgr) September 14, 2023
Nothing good just happens over night. This is all fresh and new. Marketing takes time. I was just pointing out the progress not saying you're about to get rich overnight pumping crap lol. I see where you stand though bahahahaha.
That's huge. Their Twitter posts are getting hundreds of thousands of views.
Let's go!!!
A lot of happy investors in here. Looks like there may be something going on with $MSRM and $BLEG from Twitter. Anyone else follow that?
Right.
They say the best things come in giant packages. Maybe you'll surprise yourself and find it worth the read!
Well, I figured if I made it giant, it would match your giant personality!
Well this got interesting over here. 🤣
With a market capitalization of almost $7 million and a strong share structure, BLEG Branded Legacy offers a compelling investment opportunity in the biotech sector. Let's explore why investing in Branded Legacy is the smart choice:
1. Biotech Expertise: Branded Legacy possesses a team of seasoned experts, scientists, and visionaries who are dedicated to pushing the boundaries of biotechnology. They focus on pioneering research and development initiatives, cutting-edge treatments, and innovative therapies that have the potential to transform the healthcare landscape.
2. Market Potential: The biotech industry is experiencing an era of unprecedented growth and innovation, with breakthrough discoveries and life-saving treatments emerging at an accelerating pace. Branded Legacy is strategically positioned to leverage these advancements, capture market opportunities, and maximize returns for its investors.
3. Share Structure: Branded Legacy maintains a robust share structure, with authorized shares of 3 billion and outstanding shares of over 2.8 billion. This structure ensures equitable participation for investors and provides a strong foundation for sustained growth. Based on the disclosure, most of the I/O is owned by the CEO. This is good.
4. Restricted and Unrestricted Shares: Branded Legacy holds a significant proportion of restricted shares, with 2.35 billion shares, demonstrating its long-term commitment to stability and value appreciation. The presence of 62.7 million unrestricted shares also ensures liquidity and flexibility, empowering investors to make informed decisions and seize market opportunities.
5. Held at DTC: Branded Legacy's shares held at the Depository Trust Company (DTC), totaling 62.7 million.
6. Strong Float: Branded Legacy boasts a substantial float of 49.9 million shares, enhancing investor liquidity and facilitating seamless market participation. This strong float enables efficient buying and selling, allowing investors to respond swiftly to market dynamics and capitalize on emerging trends.
7. Breakthrough Innovations: Branded Legacy is committed to discovering, developing, and commercializing groundbreaking biotech solutions that address unmet medical needs. Their robust pipeline of promising therapies and novel technologies positions them to deliver transformative advancements, generate revenue growth, and create sustainable value for its investors.
8. Investor Engagement: Branded Legacy values the trust and support of its investors. They prioritize effective communication, regular updates, and transparency to ensure that its shareholders ensuring all are well-informed about its progress, milestones, and strategic initiatives.
GLTA
$BLEG
With a market capitalization of almost $7 million and a strong share structure, BLEG Branded Legacy offers a compelling investment opportunity in the biotech sector. Let's explore why investing in Branded Legacy is the smart choice:
1. Biotech Expertise: Branded Legacy possesses a team of seasoned experts, scientists, and visionaries who are dedicated to pushing the boundaries of biotechnology. They focus on pioneering research and development initiatives, cutting-edge treatments, and innovative therapies that have the potential to transform the healthcare landscape.
2. Market Potential: The biotech industry is experiencing an era of unprecedented growth and innovation, with breakthrough discoveries and life-saving treatments emerging at an accelerating pace. Branded Legacy is strategically positioned to leverage these advancements, capture market opportunities, and maximize returns for its investors.
3. Share Structure: Branded Legacy maintains a robust share structure, with authorized shares of 3 billion and outstanding shares of over 2.8 billion. This structure ensures equitable participation for investors and provides a strong foundation for sustained growth. Based on the disclosure, most of the I/O is owned by the CEO. This is good.
4. Restricted and Unrestricted Shares: Branded Legacy holds a significant proportion of restricted shares, with 2.35 billion shares, demonstrating its long-term commitment to stability and value appreciation. The presence of 62.7 million unrestricted shares also ensures liquidity and flexibility, empowering investors to make informed decisions and seize market opportunities.
5. Held at DTC: Branded Legacy's shares held at the Depository Trust Company (DTC), totaling 62.7 million.
6. Strong Float: Branded Legacy boasts a substantial float of 49.9 million shares, enhancing investor liquidity and facilitating seamless market participation. This strong float enables efficient buying and selling, allowing investors to respond swiftly to market dynamics and capitalize on emerging trends.
7. Breakthrough Innovations: Branded Legacy is committed to discovering, developing, and commercializing groundbreaking biotech solutions that address unmet medical needs. Their robust pipeline of promising therapies and novel technologies positions them to deliver transformative advancements, generate revenue growth, and create sustainable value for its investors.
8. Investor Engagement: Branded Legacy values the trust and support of its investors. They prioritize effective communication, regular updates, and transparency to ensure that its shareholders ensuring all are well-informed about its progress, milestones, and strategic initiatives.
GLTA
$BLEG
With a market capitalization of almost $7 million and a strong share structure, BLEG Branded Legacy offers a compelling investment opportunity in the biotech sector. Let's explore why investing in Branded Legacy is the smart choice:
1. Biotech Expertise: Branded Legacy possesses a team of seasoned experts, scientists, and visionaries who are dedicated to pushing the boundaries of biotechnology. They focus on pioneering research and development initiatives, cutting-edge treatments, and innovative therapies that have the potential to transform the healthcare landscape.
2. Market Potential: The biotech industry is experiencing an era of unprecedented growth and innovation, with breakthrough discoveries and life-saving treatments emerging at an accelerating pace. Branded Legacy is strategically positioned to leverage these advancements, capture market opportunities, and maximize returns for its investors.
3. Share Structure: Branded Legacy maintains a robust share structure, with authorized shares of 3 billion and outstanding shares of over 2.8 billion. This structure ensures equitable participation for investors and provides a strong foundation for sustained growth. Based on the disclosure, most of the I/O is owned by the CEO. This is good.
4. Restricted and Unrestricted Shares: Branded Legacy holds a significant proportion of restricted shares, with 2.35 billion shares, demonstrating its long-term commitment to stability and value appreciation. The presence of 62.7 million unrestricted shares also ensures liquidity and flexibility, empowering investors to make informed decisions and seize market opportunities.
5. Held at DTC: Branded Legacy's shares held at the Depository Trust Company (DTC), totaling 62.7 million.
6. Strong Float: Branded Legacy boasts a substantial float of 49.9 million shares, enhancing investor liquidity and facilitating seamless market participation. This strong float enables efficient buying and selling, allowing investors to respond swiftly to market dynamics and capitalize on emerging trends.
7. Breakthrough Innovations: Branded Legacy is committed to discovering, developing, and commercializing groundbreaking biotech solutions that address unmet medical needs. Their robust pipeline of promising therapies and novel technologies positions them to deliver transformative advancements, generate revenue growth, and create sustainable value for its investors.
8. Investor Engagement: Branded Legacy values the trust and support of its investors. They prioritize effective communication, regular updates, and transparency to ensure that its shareholders ensuring all are well-informed about its progress, milestones, and strategic initiatives.
GLTA
$BLEG
Branded Legacy and Novus Partner to Develop Plant-Based Meds for Health Plans
Source: InvestorsHub NewsWire
Branded Legacy and Novus Partner to Develop Plant-Based Meds for Health Plans
Melbourne, FL -- September 12, 2023 -- InvestorsHub NewsWire -- Branded Legacy, Inc (OTC.PK: BLEG), an emerging biotechnology company, is excited to announce a strategic partnership with Novus Acquisition & Development Corp (OTC.PK: NDEV), a national supplemental health insurance carrier that is a pioneer in offering cannabis-embedded health plans for both recreational and medical use. This collaboration marks a significant milestone in Branded Legacy's mission to revolutionize the biotechnology landscape while creating a profound impact on the healthcare industry.
The collaboration will entail Novus's expansive distribution network of dispensaries across the United States. It will serve as a distributor, promoting Branded Legacy's formularies to their policyholders and those within health carriers that incorporate Novus benefit packages.
The deal will entail the following:
Point of Sale Integration: Novus will seamlessly integrate Legacy Brands' formularies into dispensaries and healthcare facilities'. This ensures policyholders can easily access Legacy's prescriptions when visiting these locations.
Dual Role as Pharmacy Benefits Manager and Health Carrier: Making Novus a key player in distributing Legacy's formularies to policyholders at the point of sale and wholesale level. This partnership has the potential to enhance the availability and affordability of proprietary cannabis-based treatments significantly.
David Oswald, CEO of Branded Legacy, said; "That the collaboration with Novus is a significant milestone in our mission to develop proprietary formularies tailored to both companies' needs and based on data identifying the most profitable products".
Frank Labrozzi, CEO of Novus, commented, "The collaboration between health insurance and biotech has been fruitful over the years, and this partnership is no exception. Our objective is to provide Branded Legacy well-researched cannabis-based formularies to Americans, offering them more effective and affordable treatment options."
The winds of change are happening; cannabis legalization is advancing, unlocking fresh and inventive avenues for research. As legal barriers shift, researchers now have a distinctive opportunity to delve into this plant's medical, therapeutic, and economic possibilities. This wave of transformation holds the promise of thrilling discoveries that could reshape various industries.
Branded Legacy looks forward to working closely with Novus to bring innovative therapies and solutions to patients while creating long-term value for stakeholders.
About Branded Legacy
Branded Legacy Inc. (OTC.PK: BLEG), is a forward-thinking biotechnology company committed to driving innovation in plant-derived medicines and biotechnological breakthroughs. The company's strategic partnerships and milestone achievements highlight its dedication to transforming patient care and contributing to the advancement of healthcare solutions.
About Novus Acquisition & Development Corp.
Novus Acquisition & Development Corp. (NDEV) functions via its subsidiary, WCIG Insurance Services,Inc. which operates as a health insurance carrier. It offers health insurance policies incorporating medical cannabis benefits alongside various insurance offerings, such as supplemental health, life, and fixed annuities. These medical plans are available in 35 states where medical marijuana programs are legally established. Novus Website
For further updates on the Branded Legacy-Novus partnership and upcoming developments, please visit the company's website at brandedlegacy.com or contact them at INFO@BrandedLegacy.com
Media Contact
Joe Holladay
Branded Legacy
Phone: 321-345-3565
Email: info@brandedlegacy.com
Website: https://brandedlegacy.com/
Safe Harbor Statement on Forward-Looking Language:
This release includes forward-looking statements, which are based on certain assumptions and reflect management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include general global economic conditions; general industry and market conditions and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, includes codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. Dilution, if any, would be for the purposes of management taking stock in lieu of cash salary. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Additionally, this press release that is not statements of historical fact may be considered to be forward-looking statements. Written words such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," or variations of these or similar words, identify forward-looking statements. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the near future.
$BLEG and $NDRV to Develop Plant-Based Meds for Health Plans 📈
Pink Current today. That's good.
The live discussion with CEO happened already.
Except we're in an alternative reporting world. So all those shares whether it was debt that converted into shares or it was shares issued for the purchase of a company all would come with some sort of restriction. The company cannot issue free trading shares like that.
More than likely it was a share purchase.
Debt financing, equity offerings, or any other “normal” method of raising funds all will end up with shares issued to pay people back. If the marketing company equally believes in what branded legacy is doing, then taking an equity position may make sense for them.
Pretty much the same impact on a shareholders actually kind of better because you don't have a toxic note holder excessively reducing the share price through selling to recoup their investment.
The company isn't fust bring a product to market for FDA approval. They provide services for biotech companies that need to be marketed.
$BLEG Acquires Rocket Web Development and Design
Strategic acquisition closes to enable in-house marketing and development.
Melbourne, Florida, – August 15, 2023 – Branded Legacy, a holdings company focused on biotechnology, is pleased to announce that it has completed the acquisition of Rocket Web Development and Design (RWDD). This significant milestone underscores Branded Legacy’s commitment to expanding its digital capabilities and providing cutting-edge web solutions to it’s subsidiaries and clients.
RWDD is a respected full-service web development and online marketing firm with a successful track record spanning over seven years. The company is poised to leverage RWDD’s expertise to enhance its online presence and support the growth of its web-based services.
Doug Holladay, Chief Executive Officer of Rocket Web Development and Design, expressed his excitement about the acquisition, stating, “We are thrilled to be a part of Branded Legacy’s journey. This acquisition signifies a pivotal step in expanding our operations and reaching larger marketing and production targets. We look forward to joining forces and combining our strengths to provide innovative digital solutions that align with Branded Legacy’s vision.”
David Oswald, Chief Executive Officer and Chairman of Branded Legacy, also commented on the closure of the RWDD acquisition, saying, “The acquisition of Rocket Web Development and Design reflects our strategic focus on enhancing our digital capabilities. We are pleased to have completed the final stages of this acquisition and welcome RWDD into the Branded Legacy family. This collaboration will enable us to further support our clients and solidify our position as a prominent player in both the biotechnology and digital sectors.”
As the RWDD acquisition progresses toward completion, Branded Legacy remains dedicated to advancing scientific innovation, improving patient care, and delivering exceptional value to its stakeholders.
Additionally, Branded Legacy would like to announce that the acquisition of MycoEnlighten LLC has been suspended due to issues uncovered during due diligence. We are exploring options to continue working together as corporate partners to bring their exciting products to market.
For further updates on RWDD and other developments at Branded Legacy, please visit the company’s website at brandedlegacy.com or contact them at INFO@BrandedLegacy.com
$BLEG Acquires Rocket Web Development and Design
Strategic acquisition closes to enable in-house marketing and development.
Melbourne, Florida, – August 15, 2023 – Branded Legacy, a holdings company focused on biotechnology, is pleased to announce that it has completed the acquisition of Rocket Web Development and Design (RWDD). This significant milestone underscores Branded Legacy’s commitment to expanding its digital capabilities and providing cutting-edge web solutions to it’s subsidiaries and clients.
RWDD is a respected full-service web development and online marketing firm with a successful track record spanning over seven years. The company is poised to leverage RWDD’s expertise to enhance its online presence and support the growth of its web-based services.
Doug Holladay, Chief Executive Officer of Rocket Web Development and Design, expressed his excitement about the acquisition, stating, “We are thrilled to be a part of Branded Legacy’s journey. This acquisition signifies a pivotal step in expanding our operations and reaching larger marketing and production targets. We look forward to joining forces and combining our strengths to provide innovative digital solutions that align with Branded Legacy’s vision.”
David Oswald, Chief Executive Officer and Chairman of Branded Legacy, also commented on the closure of the RWDD acquisition, saying, “The acquisition of Rocket Web Development and Design reflects our strategic focus on enhancing our digital capabilities. We are pleased to have completed the final stages of this acquisition and welcome RWDD into the Branded Legacy family. This collaboration will enable us to further support our clients and solidify our position as a prominent player in both the biotechnology and digital sectors.”
As the RWDD acquisition progresses toward completion, Branded Legacy remains dedicated to advancing scientific innovation, improving patient care, and delivering exceptional value to its stakeholders.
Additionally, Branded Legacy would like to announce that the acquisition of MycoEnlighten LLC has been suspended due to issues uncovered during due diligence. We are exploring options to continue working together as corporate partners to bring their exciting products to market.
For further updates on RWDD and other developments at Branded Legacy, please visit the company’s website at brandedlegacy.com or contact them at INFO@BrandedLegacy.com
May 12, 2023 | Branded Legacy, Inc. Retains Counsel to File S-1 Registration Statement
~~Company Plans to Up-List to OTCQB
https://tinyurl.com/5xdnnpvk
May 12, 2023 | Branded Legacy, Inc. Retains Counsel to File S-1 Registration Statement
~~Company Plans to Up-List to OTCQB
https://tinyurl.com/5xdnnpvk
Jun 30, 2023 | Branded Legacy, Inc. Welcomes New Management Team and Announces Strategic Transformation Into Biotech Industry
~~Company Plans Name and Symbol Change to Align With Operational Pivot into Biotech Sector
https://tinyurl.com/4v6pk3e2
Jun 30, 2023 | Branded Legacy, Inc. Welcomes New Management Team and Announces Strategic Transformation Into Biotech Industry
~~Company Plans Name and Symbol Change to Align With Operational Pivot into Biotech Sector
https://tinyurl.com/4v6pk3e2
What makes it big is you could have the best product in the world It's not going to move itself. Marketing is essential and marketing gets very expensive. Having that in-house is a huge asset more so than just revenues it reduces expenses for the company.
Not sure they weren't specific. They sent out a tweet that the company had revenues My guess is they're low otherwise they would announce it. But not having to pay for marketing because it's in-house is huge. Marketing gets expensive and it's vital for any company especially a newer startup company.
Negative no matter what huh 🤣
Now your upset that the marketing acquisition went through and not the mycology company.
Keep your head up my man.
GLTA
Big acquisition last week. Thought that would have caught more eyes. BLEG is doing it 📈
$CAFI Consumer Automotive Finance, Inc. Announces New State-of-the-Art Corporate Headquarters, Accelerating Expansion into Sports and Nutrition Industry.
📈
$CAFI Consumer Automotive Finance, Inc. Announces New State-of-the-Art Corporate Headquarters, Accelerating Expansion into Sports and Nutrition Industry.
📈
$CAFI Consumer Automotive Finance, Inc. Announces New State-of-the-Art Corporate Headquarters, Accelerating Expansion into Sports and Nutrition Industry.
📈
🏃 is coming. Price is undervalued, new acquisition, etc. Transparent board.
Let's get this over .01 again 📈
$BLEG Updates on OTC
BLEG[t][/t]
✅ Steven Augustine - Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member
✅ David Oswald- Audit Committee Member, Compensation Committee Member, Nominating Committee Member
✅ Andrew Seelund - Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member
✅Phillip White- Audit Committee Member, Compensation Committee Member, Nominating Committee Member
$BLEG Updates on OTC
BLEG[t][/t]
✅ Steven Augustine - Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member
✅ David Oswald- Audit Committee Member, Compensation Committee Member, Nominating Committee Member
✅ Andrew Seelund - Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member
✅Phillip White- Audit Committee Member, Compensation Committee Member, Nominating Committee Member
$BLEG Updates on OTC
BLEG
✅ Steven Augustine - Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member
✅ David Oswald- Audit Committee Member, Compensation Committee Member, Nominating Committee Member
✅ Andrew Seelund - Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member
✅Phillip White- Audit Committee Member, Compensation Committee Member, Nominating Committee Member
No clue.
Snooze fenix in for a huge awakening.
Brandon's Netflix series Untold: Swamp Kings
And
10 new product launches
All set for August. Huge upside potential. HUGE.
Don't snooze for too long there Fenix, Invest.
$CAFI
Just my opinion.
GLTA
All time low? I don't see that at all. CEO just adequately closed his first acquisition adding more revenues to $BLEG.
The CEO also wants a name change to which I kind of like Branded Legacy but who knows. Maybe a new name is the secret sauce.